MedKoo Cat#: 555107 | Name: BMY-27709

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMY-27709 is an inhibitor of influenza virus growth. BMY-27709 has an IC50 of 3-8 microM for A/WSN/33 virus growth in a multicycle replication assay and is active against all H1 and H2 subtype viruses tested. However, BMY-27709 was found to be inactive against H3 subtype viruses, as well as influenza B/Lee/40 virus. BMY-27709 was also found to act against H1 and H2 viruses early in infection, suggesting that the target for inhibition is the hemagglutinin protein.

Chemical Structure

BMY-27709
CAS#99390-76-8

Theoretical Analysis

MedKoo Cat#: 555107

Name: BMY-27709

CAS#: 99390-76-8

Chemical Formula: C17H24ClN3O2

Exact Mass: 337.1557

Molecular Weight: 337.85

Elemental Analysis: C, 60.44; H, 7.16; Cl, 10.49; N, 12.44; O, 9.47

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMY-27709; BMY 27709; BMY27709;
IUPAC/Chemical Name
4-amino-5-chloro-2-hydroxy-N-((2S,6R,9aR)-6-methyloctahydro-2H-quinolizin-2-yl)benzamide
InChi Key
SQQXDSFKORQHET-GRYCIOLGSA-N
InChi Code
InChI=1S/C17H24ClN3O2/c1-10-3-2-4-12-7-11(5-6-21(10)12)20-17(23)13-8-14(18)15(19)9-16(13)22/h8-12,22H,2-7,19H2,1H3,(H,20,23)/t10-,11+,12-/m1/s1
SMILES Code
C[C@@H]1CCC[C@H]2N1CC[C@@H](C2)NC(=O)C3=CC(=C(C=C3O)N)Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 337.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. Review. PubMed PMID: 18220789. 2: Yu KL, Torri AF, Luo G, Cianci C, Grant-Young K, Danetz S, Tiley L, Krystal M, Meanwell NA. Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3379-82. PubMed PMID: 12419365. 3: Deshpande MS, Wei J, Luo G, Cianci C, Danetz S, Torri A, Tiley L, Krystal M, Yu KL, Huang S, Gao Q, Meanwell NA. An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2393-6. PubMed PMID: 11527739. 4: Combrink KD, Gulgeze HB, Yu KL, Pearce BC, Trehan AK, Wei J, Deshpande M, Krystal M, Torri A, Luo G, Cianci C, Danetz S, Tiley L, Meanwell NA. Salicylamide inhibitors of influenza virus fusion. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1649-52. PubMed PMID: 10937716. 5: Cianci C, Yu KL, Dischino DD, Harte W, Deshpande M, Luo G, Colonno RJ, Meanwell NA, Krystal M. pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion. J Virol. 1999 Mar;73(3):1785-94. PubMed PMID: 9971755; PubMed Central PMCID: PMC104417. 6: Shigeta S. [Current status of research and development for anti-influenza virus drugs--chemotherapy for influenza]. Nihon Rinsho. 1997 Oct;55(10):2758-64. Review. Japanese. PubMed PMID: 9360403. 7: Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol. 1997 May;71(5):4062-70. PubMed PMID: 9094684; PubMed Central PMCID: PMC191559. 8: Luo G, Colonno R, Krystal M. Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Virology. 1996 Dec 1;226(1):66-76. PubMed PMID: 8941323.